Bli medlem
Bli medlem

Du är här

2016-11-02

Nexstim Oyj: Nexstim Plc issues shares in standby equity distribution agreement pursuant to the financing arrangement announced on 21 July 2016

Company announcement, Helsinki, 2 November 2016, at 9 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim
" or the "Company
"), a medical technology company with a pioneering navigated non-invasive
brain stimulation system, announces that, pursuant to the authorisations
received at the Company's extraordinary general meeting on 18 August 2016 and
the financing arrangement entered into with Bracknor Investment and the
Finnish Innovation Fund Sitra which was announced on 21 July 2016, the Board
of Directors of the Company has today resolved on issuing 1,379,490 shares to
Bracknor with a subscription price of EUR 333,008.88 based on the stand-by
equity distribution agreement (SEDA). The Board of Directors of the Company
has also decided to issue 1,498,868 treasury shares to the Company itself
without consideration and list the afore mentioned shares. The new shares
will be listed approximately on 9 November 2016. After the transfer the
Company will have 1,498,868 treasury shares. After the issuance, the total
number of registered shares in the Company will be 14,988,686.

Martin Jamieson, Chairman and CEO of Nexstim, commented:
"In line with the funding agreement announced in July, we are pleased to be
able to continue to raise capital via this favourable first use of the
standby equity distribution agreement. As previously stated, we estimate this
will provide funding until the beginning of Financial year 2018 as we
continue to focus on the FDA 510(k) De Novo regulatory approval for Stroke
Rehabilitation, utilising our Navigated Brain Therapy (NBT®) system''.

NEXSTIM PLC
Martin Jamieson, CEO

Further information is available on the website
www.nexstim.comor by contacting:

Nexstim

+447715163942
Martin Jamieson, Chief Executive Officer
martin.jamieson@nexstim.com

UB Securities Oy
(Certified Adviser)
+358 (0)9 2538 0246

Consilium Strategic Communications
+44 (0)20
3709 5700
Mary-Jane Elliott / Ivar Milligan
nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in
brain diagnostics with the Navigated Brain Stimulation (NBS) system as the
first and only FDA-cleared and CE-marked navigated Transcranial Magnetic
Stimulation (nTMS) system for pre-surgical mapping of the motor and speech
cortices. Based on the same technology platform, the Company has developed a
system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic
neuropathic pain, major depression and stroke therapy. Nexstim's shares are
listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more
information please visitwww.nexstim.com

Nexstim Plc
http://hugin.info/138152/R/2053530/768591.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.